[Effects of Guizhi Fuling Decoction on YKL-40 and hs-CRP of patients with non-ST segment elevation acute coronary syndrome]
- PMID: 23646472
[Effects of Guizhi Fuling Decoction on YKL-40 and hs-CRP of patients with non-ST segment elevation acute coronary syndrome]
Abstract
Objective: To investigate the changes of serum levels of chitinase-3-like-1 protein (YKL-40) and high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST segment elevation acute coronary syndrome (ACS), to explore its correlation with its severity, and to observe the effects of Guizhi Fuling Decoction (GFD) on levels of blood lipids, YKL-40, and hs-CRP.
Methods: Recruited were 72 patients with unstable angina (UA) or non-ST segment elevation myocardial infarction (NSTEMI) at Department of Integrative Medicine, First Affiliated Hospital of Xinxiang Medical College from August 2010 to June 2011. They were randomly assigned to the treatment group (36 cases) and the control group (36 cases). All patients were treated by routine treatment, but patients in the treatment group took GFD additionally. The course of treatment was four weeks. According to the severity degree, all patients were graded to four ranks: low-risk group of UA, medium-risk group of UA, high-risk group of UA, and NSTEMI. The levels of YKL-40 and hs-CRP, and the correlation of severity degree were analyzed. Before and after treatment levels of triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) were measured. Before treatment, at two weeks, and after treatment the serum levels of YKL-40 and hs-CRP were detected. The relationship of YKL-40, hs-CRP and the severity of the disease were analyzed.
Results: Levels of YKL-40 and hs-CRP were positively correlated with the severity of the disease respectively (r = 0.729, P < 0.05; r = 0.655, P < 0.05). The positive correlation also existed between YKL-40 and hs-CRP (r = 0.848, P < 0.05). There was no statistical difference in the levels of blood lipids, YKL-40, or hs-CRP between the two groups before treatment (P > 0.05). Compared with before treatment, the levels of YKL-40 and hs-CRP significantly decreased in both groups after two weeks of treatment (P < 0.05). The levels of TG, TC, LDL-C, YKL-40, and hs-CRP significantly decreased, while the HDL-C level increased in both groups after treatment (P < 0.05). The level of HDL-C in the treatment group was higher, while levels of YKL-40 and hs-CRP were lower after treatment, when compared with the control group (all P < 0.05).
Conclusion: On the basis of anti-inflammation and adjusting blood lipids by Western medicine, GFD could further reduce the serum levels of YKL-40 and hs-CRP of ACS patients, elevate the HDL-C level, and play anti-atherosclerosis effects.
Similar articles
-
[Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Dec;31(12):1607-10. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011. PMID: 22384544 Clinical Trial. Chinese.
-
Study on the levels of uric acid and high-sensitivity C-reactive protein in ACS patients and their relationships with the extent of the coronary artery lesion.Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4294-4298. Eur Rev Med Pharmacol Sci. 2016. PMID: 27831644
-
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023. Clin Ther. 2008. PMID: 19167589 Clinical Trial.
-
Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis.Medicine (Baltimore). 2024 Jan 19;103(3):e36588. doi: 10.1097/MD.0000000000036588. Medicine (Baltimore). 2024. PMID: 38241594 Free PMC article.
-
Danhong injection in the treatment of acute coronary syndrome: a systematic review and meta-analysis.Am J Chin Med. 2015;43(2):199-214. doi: 10.1142/S0192415X15500135. Epub 2015 Mar 19. Am J Chin Med. 2015. PMID: 25787298
Cited by
-
Efficacy and Safety of Shenqisuxin Granule for Non-ST-segment Elevation Acute Coronary Syndrome: Study Protocol for a Randomized, Double-Blinded, Placebo-Controlled Trial.Front Cardiovasc Med. 2022 Jun 9;9:888724. doi: 10.3389/fcvm.2022.888724. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35757330 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous